{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:33:39Z","timestamp":1790386419058,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2019,9,1]]},"DOI":"10.1007\/s40123-019-0191-9","type":"journal-article","created":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T05:25:27Z","timestamp":1561181127000},"page":"485-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"8","author":[{"given":"Adrien","family":"Maudinet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Law-Koune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Duretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Lasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Modiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-7092","authenticated-orcid":false,"given":"Thi Ha Chau","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,22]]},"reference":[{"issue":"10086","key":"191_CR1","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"key":"191_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","volume":"54","author":"Z Ou","year":"2018","unstructured":"Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303\u201310.","journal-title":"Int Immunopharmacol"},{"issue":"24","key":"191_CR3","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"191_CR4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018;178(5):1083\u2013101.","journal-title":"Br J Dermatol"},{"key":"191_CR5","doi-asserted-by":"crossref","unstructured":"Bakker DS, Ariens LFM, van Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180(5):1248\u20131249.","DOI":"10.1111\/bjd.17538"},{"issue":"5","key":"191_CR6","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","volume":"6","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegraber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6(5):1778\u20131780.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"191_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","volume":"7","author":"AC Barnes","year":"2017","unstructured":"Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated with dupilumab. Am J Ophthalmol Case Rep. 2017;7:120\u20132.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"191_CR8","doi-asserted-by":"publisher","unstructured":"Shen E, Xie K, Jwo K, Smith J, Mosaed S. Dupilumab-induced follicular conjunctivitis. Ocular Immunol Inflamm. 2018;1\u20133. https:\/\/doi.org\/10.1080\/09273948.2018.1533567.","DOI":"10.1080\/09273948.2018.1533567"},{"issue":"1","key":"191_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jdcr.2018.10.016","volume":"5","author":"MJ Zirwas","year":"2019","unstructured":"Zirwas MJ, Wulff K, Beckman K. Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report. JAAD Case Rep. 2019;5(1):34\u20136.","journal-title":"JAAD Case Rep"},{"issue":"10","key":"191_CR10","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","volume":"154","author":"AD Treister","year":"2018","unstructured":"Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208\u201311.","journal-title":"JAMA Dermatol"},{"key":"191_CR11","doi-asserted-by":"publisher","unstructured":"Yamane MLM, Belsito DV, Glass LRD. Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis. Orbit. 2019;1\u20135. https:\/\/doi.org\/10.1080\/01676830.2018.1553190.","DOI":"10.1080\/01676830.2018.1553190"},{"issue":"12","key":"191_CR12","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","volume":"154","author":"RM Levine","year":"2018","unstructured":"Levine RM, Tattersall IW, Gaudio PA, King BA. Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management. JAMA Dermatol. 2018;154(12):1485\u20136.","journal-title":"JAMA Dermatol"},{"issue":"26","key":"191_CR13","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475\u201385.","journal-title":"N Engl J Med"},{"issue":"5\u20136","key":"191_CR14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3109\/08820538.2013.874483","volume":"30","author":"M Nebbioso","year":"2015","unstructured":"Nebbioso M, Zicari AM, Celani C, Lollobrigida V, Grenga R, Duse M. Pathogenesis of vernal keratoconjunctivitis and associated factors. Semin Ophthalmol. 2015;30(5\u20136):340\u20134.","journal-title":"Semin Ophthalmol"},{"issue":"5","key":"191_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ophtha.2018.12.027","volume":"126","author":"A Leonardi","year":"2019","unstructured":"Leonardi A, Doan S, Amrane M, et al. A randomized, controlled trial of cyclosporine a cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS Study. Ophthalmology. 2019;126(5):671\u201381.","journal-title":"Ophthalmology"},{"issue":"11","key":"191_CR16","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1167\/iovs.16-19757","volume":"57","author":"DC Jackson","year":"2016","unstructured":"Jackson DC, Zeng W, Wong CY, et al. Tear interferon-gamma as a biomarker for evaporative dry eye disease. Invest Ophthalmol Vis Sci. 2016;57(11):4824\u201330.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-019-0191-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-019-0191-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-019-0191-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:57:16Z","timestamp":1713283036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-019-0191-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,22]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9,1]]}},"alternative-id":["191"],"URL":"https:\/\/doi.org\/10.1007\/s40123-019-0191-9","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,22]]},"assertion":[{"value":"9 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}